Home/Filings/4/0001567619-20-018006
4//SEC Filing

Symons Julian A. 4

Accession 0001567619-20-018006

CIK 0001799448other

Filed

Oct 19, 8:00 PM ET

Accepted

Oct 20, 4:57 PM ET

Size

13.9 KB

Accession

0001567619-20-018006

Insider Transaction Report

Form 4
Period: 2020-10-20
Symons Julian A.
See Remarks
Transactions
  • Conversion

    Common Stock

    2020-10-20+3,394392,612 total
  • Conversion

    Series B-2 Preferred Stock

    2020-10-201,4520 total
    Common Stock (1,452 underlying)
  • Conversion

    Series A Preferred Stock

    2020-10-2013,6710 total
    Common Stock (13,671 underlying)
  • Conversion

    Common Stock

    2020-10-20+13,671389,218 total
  • Conversion

    Common Stock

    2020-10-20+1,452394,064 total
  • Conversion

    Series B-1 Preferred Stock

    2020-10-203,3940 total
    Common Stock (3,394 underlying)
Footnotes (1)
  • [F1]Each share of the issuer's Series A Preferred Stock, Series B-1 Preferred Stock and Series B-2 Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on October 20, 2020 and had no expiration date.

Documents

1 file

Issuer

Aligos Therapeutics, Inc.

CIK 0001799448

Entity typeother

Related Parties

1
  • filerCIK 0001824727

Filing Metadata

Form type
4
Filed
Oct 19, 8:00 PM ET
Accepted
Oct 20, 4:57 PM ET
Size
13.9 KB